現(xiàn)代脂質(zhì)三聯(lián)治療ppt課件-展示頁
2025-01-25 11:38本頁面
【正文】 HDL LDL/HDL Ratio The Lipid Triad The LDL/HDL Ratio Our Strength, Our Story!! Clear positioning for Lipobay A new perception of efficacy Differentiation to Atorvastatin Fit with our product profile LDL HDL Additional risk factor, especially in diabetics The Lipid Triad Overview TG The Lipid Triad The Ratio The Lipid Triad and Strategic Rationale Part II ? No scientific evidence ? Evidence contradicting this statement ? A marketing hypothesis to build their LDL story ? Creating the perception of the statin with the strongest efficacy It’s logical It’s measurable It’s practicable The Lipid Triad The GP’s Perspective Supporting Data from Landmark Studies Part III 12 10 8 6 4 2 0 % Mortality Placebo Q1 Q2 Q3 Q4 (low HDLincrease) (high HDLincrease) 4S Study CAD Mortality per Quartiles of Increases in HDLCholesterol KJEKSHUS J amp。 PEDERSEN T (unpublished) HDL Intervention Trial (VAHIT) RUBINS HB et al. New Engl J Med 1999。 LDLC showed a 22% reduction in bined fatal and nonfatal MI HDL Cholesterol as Risk Factor for CHD LRC CPPT (Placebo) MRFIT (usual care) Incidence rate of CHD Incidence rate of CHD 12 10 8 6 4 2 0 100 130 160 190 GORDON DJ et al. Circulation 1989。 82:6065 220 160 100 85 65 45 25 LDL Cholesterol (mg/dL) 0 2 4 6 8 10 12 14 16 LDL=5 LDL5 HDL= HDL LDL/HDL=5 LDL/HDL5 Incidence of cardiac events (per 1000 personyears) Gemfibrozil Placebo LDLC Tertiles (mmol/L) HDLC Tertiles (mmol/L) LDLC/HDLC Tertiles 24 46 32 36 34 45 22 39 38 53 18 29 Incidence for cardiac events vs lipid parameter Helsinki Heart Study MANNINEN V, Leena T, Koskinen P et al. Circulation 1992。 101: 477484 LDL/HDL Ratio as Therapeutic Success Placebo Statin 24 116 31 245 0 50 100 150 200 250 300 = 5 5 LDL / HDL Ratio Triglycerides 200 mg/dl Triglycerides = 200 mg/dl CAD cases per 1,000 subjects in 6 years ASSMANN G and
教學課件相關推薦
鄂ICP備17016276號-1